These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Perspectives for the development of preventive vaccines against HIV/AIDS]. Esparza J Medicina (B Aires); 1998; 58 Suppl 1():57-63. PubMed ID: 9674249 [No Abstract] [Full Text] [Related]
23. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. Angel JB AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678 [TBL] [Abstract][Full Text] [Related]
24. The need for novel targets and approaches to HIV therapy. Martinez LJ Res Initiat Treat Action; 2002; 8(1):23-5. PubMed ID: 12489523 [No Abstract] [Full Text] [Related]
25. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. Robinson HL; Weinhold KJ J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331 [No Abstract] [Full Text] [Related]
26. Trial suggests vaccines could aid HIV therapy. Check E Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722 [No Abstract] [Full Text] [Related]
27. [Vaccines against HIV]. Holm-Hansen C Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118 [TBL] [Abstract][Full Text] [Related]
28. Remune bites the dust...again. Vázquez E Posit Aware; 2001; 12(5):21. PubMed ID: 11688479 [No Abstract] [Full Text] [Related]
29. Philadelphia area AIDS/HIV clinical trials. Crit Path AIDS Proj; 1997; (No 32):35-44. PubMed ID: 11364443 [TBL] [Abstract][Full Text] [Related]
30. HIV-1 immunogen (remune). Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099 [TBL] [Abstract][Full Text] [Related]
31. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851 [TBL] [Abstract][Full Text] [Related]
32. Remune trial will stop; new trials planned. James JS AIDS Treat News; 1999 May; (No 319):1-2. PubMed ID: 11366461 [TBL] [Abstract][Full Text] [Related]
33. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP; AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838 [TBL] [Abstract][Full Text] [Related]
34. Researchers: incentives needed to boost HIV vaccines. AIDS Policy Law; 2006 Feb; 21(3):5. PubMed ID: 16511944 [No Abstract] [Full Text] [Related]
36. [The role of general practitioners in the control of HIV infection and in the treatment of seropositive and AIDS patients]. Antunes F Acta Med Port; 1997; 10(6-7):485-6. PubMed ID: 9341041 [No Abstract] [Full Text] [Related]
37. Gene therapy and HIV disease. Poeschla EM; Wong-Staal F AIDS Clin Rev; 1995-1996; ():1-45. PubMed ID: 7488553 [No Abstract] [Full Text] [Related]
38. Thailand's Prime-Boost HIV Vaccine Phase III. Trinvuthipong C Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308 [No Abstract] [Full Text] [Related]
39. [Natural history of HIV infection in adults]. Cran S Acta Urol Belg; 1993; 61(1-2):363-79. PubMed ID: 8517256 [No Abstract] [Full Text] [Related]
40. Mapping the future of HIV vaccines. Nabel GJ Nat Rev Microbiol; 2007 Jul; 5(7):482-4. PubMed ID: 17571457 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]